Pulmo BioTech Inc. And Dr. Jocelyn Dupuis Outline Original Concept Details Of Molecular Imaging Technology At 3rd International Neonatal And Childhood Pulmonary Disease Conference

NEW YORK, May 24, 2010 (GLOBE NEWSWIRE) -- Dr. Jocelyn Dupuis, the Chief Scientific Officer of Pulmo BioTech Inc. (OTCBB:PLMO) (Frankfurt:PBO) and the originator of the PulmoBind concept, has presented a paper at the 3 ^rd International Neonatal and Childhood Pulmonary Disease Conference which was held in Banff, Alberta, Canada on March 11-13 2010. The paper was titled "Development of Adrenomedullin Analogs Designed for Molecular Imaging of the Pulmonary Circulation".

Pulmo BioTech CEO Garry McCann said, "We are very pleased that Dr. Dupuis was chosen to present a paper on our Molecular Imaging technology at the Neonatal and Childhood Pulmonary Disease Conference. Pulmo BioTech believes strongly in the peer review process and academic publishing, and we are delighted to have been given the opportunity to bring to an open forum some of the technical details of our development work. We are particularly pleased that the target audience for this conference is: Pediatric and Adult Pulmonologists, Cardiology and Critical Care Physicians, Neonatology Physicians, and Advanced Practice Nurses, all of whom we would expect to be very interested in the potential applicability of PulmoBind to their specializations."

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stockholders.

ISIN: US7458451074

CUSIP: 745845107

WKN: A0RDTZ

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind™ .

PulmoScience was conceived within the Montreal Heart Institute "MHI" (a world renowned hospital and educational facility). Jointly owned by MHI subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn Dupuis (the scientific director and originator of the PulmoBind™ Molecular Imaging technology), and by Pulmo BioTech Inc. as the funding partner, PulmoScience Inc. aims to develop this unique and exciting technology, to fund necessary trials, and to bring the products to market.